With the application of statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, the LDL-C level and the risk of adverse cardiovascular events of CAD patients have been significantly decreased [6,7,8]. Here, PCSK9 is linked to coronary artery disorder.